Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging


I'm Interested

Trial ID: NCT04514692


This is a research study using Granulocyte Colony Stimulating Factor (GCSF) as a bone marrow stimulating agent for imaging to guide radiation treatment planning. G-CSF is a type of growth factor. Growth factors are proteins made in the body. G-CSF is a type of growth factor that makes the bone marrow produce white blood cells to reduce the risk of infection after some types of cancer treatment.

Official Title

Phase 1 2 Study of Individualized Bone Marrow Sparing Image Guided Radiotherapy Incorporating Novel Use of Granulocyte Colony Stimulating Factor and FDG PET Imaging

Stanford Investigator(s)

Elizabeth Kidd
Elizabeth Kidd

Associate Professor of Radiation Oncology (Radiation Therapy)


Inclusion Criteria:

   - 2018 international Federation of Gynecology and Obstetrics (FIGO) stage I IIIC1 cervix
   cancer with no prior treatment or stage IIIA IIIC1 endometrial cancer status post
   hysterectomy and lymph node assessment

   - No required para aortic or extended field radiation

   - Eastern Cooperative Oncology Group (ECOG) performance status 0 2

   - Adequate kidney function (serum Cr <1.5 or creatinine clearance >50 mg/dl)

   - Adequate bone marrow function (white blood cells > 3.0 X 109/L, platelets >100 x

   - Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

   - Treatment for other cancer in the past 2 years

   - Previous pelvic radiation

   - Medical condition that prevents receiving chemotherapy


diagnostic test: FDG PET/CT

drug: GCSF


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Neha Aidasani

New Trial Alerts